Ftse Mib
38.494,86
-0,25%
DAX
22.933,87
-0,29%
S&P 500
5.770,20
0,55%
NASDAQ
18.196,22
0,70%
Bitcoin
81.627,17
-7,24%
Pepperstone
Advertisement
Registration Strip Icon for charts Registrati per grafici in tempo reale, strumenti di analisi e prezzi.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ AcelRX Pharmaceuticals Inc (ACRX) AcelRX Pharmaceuticals Inc (ACRX) Notizie

ACRX

AcelRX Pharmaceuticals (ACRX)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:ACRX
DataOraFonteTitoloSimboloCompagnia
25/06/202401:14Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRXAcelRX Pharmaceuticals Inc
24/06/202423:24Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ACRXAcelRX Pharmaceuticals Inc
29/04/202422:25Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:ACRXAcelRX Pharmaceuticals Inc
29/04/202422:24Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:ACRXAcelRX Pharmaceuticals Inc
29/04/202422:23Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:ACRXAcelRX Pharmaceuticals Inc
09/01/202415:05PR Newswire (US)AcelRx Announces Rebranding With Name Change to Talphera, Inc.NASDAQ:ACRXAcelRX Pharmaceuticals Inc
12/12/202314:30PR Newswire (US)AcelRx Pharmaceuticals Announces Publication of Study Evaluating Anticoagulation Practices for Continuous Renal Replacement Therapy in the United StatesNASDAQ:ACRXAcelRX Pharmaceuticals Inc
01/12/202306:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ACRXAcelRX Pharmaceuticals Inc
22/11/202322:38Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:ACRXAcelRX Pharmaceuticals Inc
22/11/202322:34Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:ACRXAcelRX Pharmaceuticals Inc
14/11/202312:07Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ACRXAcelRX Pharmaceuticals Inc
08/11/202322:05PR Newswire (US)AcelRx Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:ACRXAcelRX Pharmaceuticals Inc
07/11/202322:05PR Newswire (US)AcelRx to Host KOL Panel Discussion on Current Anticoagulant Use in Dialysis and the Upcoming Niyad™ Clinical StudyNASDAQ:ACRXAcelRX Pharmaceuticals Inc
26/10/202322:30PR Newswire (US)AcelRx to Host Third Quarter 2023 Financial Results Call and Webcast on November 8, 2023NASDAQ:ACRXAcelRX Pharmaceuticals Inc
03/10/202314:30PR Newswire (US)AcelRx Receives IDE Approval for Niyad and Advances to a Single Registration StudyNASDAQ:ACRXAcelRX Pharmaceuticals Inc
06/09/202314:30PR Newswire (US)AcelRx Pharmaceuticals to Participate in the H.C. Wainwright Annual Investment ConferenceNASDAQ:ACRXAcelRX Pharmaceuticals Inc
25/08/202318:45Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ACRXAcelRX Pharmaceuticals Inc
10/08/202322:05PR Newswire (US)AcelRx Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:ACRXAcelRX Pharmaceuticals Inc
09/08/202323:29Edgar (US Regulatory)Form 424B7 - Prospectus [Rule 424(b)(7)]NASDAQ:ACRXAcelRX Pharmaceuticals Inc
28/07/202320:07Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:ACRXAcelRX Pharmaceuticals Inc
27/07/202322:05PR Newswire (US)AcelRx to Host Second Quarter 2023 Financial Results Call and Webcast on August 10, 2023NASDAQ:ACRXAcelRX Pharmaceuticals Inc
21/07/202314:00PR Newswire (US)AcelRx Pharmaceuticals Announces Closing of Previously Announced Private Placement Priced At-The-Market Under Nasdaq RulesNASDAQ:ACRXAcelRX Pharmaceuticals Inc
18/07/202314:00PR Newswire (US)AcelRx Pharmaceuticals Announces $10 Million Private Placement of Securities Priced At-The-Market Under Nasdaq RulesNASDAQ:ACRXAcelRX Pharmaceuticals Inc
15/06/202322:07Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ACRXAcelRX Pharmaceuticals Inc
10/05/202322:05PR Newswire (US)AcelRx Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:ACRXAcelRX Pharmaceuticals Inc
27/04/202322:05PR Newswire (US)AcelRx to Host First Quarter 2023 Financial Results Call and Webcast on May 10, 2023NASDAQ:ACRXAcelRX Pharmaceuticals Inc
05/04/202314:30PR Newswire (US)AcelRx Pharmaceuticals Announces Closing of Divestment of DSUVIA® to Alora PharmaceuticalsNASDAQ:ACRXAcelRX Pharmaceuticals Inc
30/03/202322:05PR Newswire (US)AcelRx Pharmaceuticals Reports Full Year and Fourth Quarter 2022 Financial Results and Provides Corporate UpdateNASDAQ:ACRXAcelRX Pharmaceuticals Inc
21/03/202321:05PR Newswire (US)AcelRx to Host Full Year and Fourth Quarter 2022 Financial Results Call and Webcast on March 30, 2023NASDAQ:ACRXAcelRX Pharmaceuticals Inc
14/03/202313:30PR Newswire (US)AcelRx Pharmaceuticals Announces Divestment of DSUVIA® to Alora PharmaceuticalsNASDAQ:ACRXAcelRX Pharmaceuticals Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:ACRX

La tua Cronologia

LSE
0OE9
Cyprus Cement Pcl
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network

Rimuovi gli annunci

Iscriviti per un'esperienza senza pubblicità

Nessuna pubblicità

Prova adesso

Conserva gli annunci